ORY Oryzon Genomics S.A.
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.…
Industry Peers
BiotechnologyKey Statistics
About Oryzon Genomics (BME: ORY)
›
Oryzon Genomics (BME: ORY) is listed on the Bolsa de Madrid, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 46 employees.
The shares were at 2.450 EUR on 19 November 2026, down 19.1% over 52 weeks. Its 52-week range is 2.230 EUR to 3.560 EUR: the price is 31.2% below the high and 9.9% above the low.
Its market capitalisation is 200.80M EUR.
Oryzon Genomics reports return on equity of -2.2% and an operating margin of 0.0%.
Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 8.100 EUR is 230.6% above the current price. The next earnings report is expected on 11 February 2027.